REPEAT – AgraFlora’s Subsidiary Farmako Secures Additional Supply of EU-GMP Cannabis via Definitive Supply Agreement with...
15 9월 2020 - 11:33PM
AgraFlora Organics International
Inc. (“
AgraFlora”
or the “
Company”)
(
CSE: AGRA
) (Frankfurt:
PU31
) (OTCPK: AGFAF) is pleased to announce that
its wholly owned subsidiary Farmako GmbH
(“
Farmako”) has executed the binding supply
agreement (the “
Supply Agreement”) with ZenPharm
Ltd (“
ZenPharm”), a subsidiary of Zenabis Global
Inc. (TSX: ZENA) (“
Zenabis”).
Pursuant to the Supply Agreement, ZenPharm will
supply EU-GMP quality medical cannabis flower cultivated by Zenabis
to Farmako for distribution to medical cannabis patients in
Germany. The agreement is intended to facilitate the distribution
of 1,500 kilograms of cannabis flower by Farmako in Germany over a
3 year term. Farmako will distribute the products to its
established network of German pharmacies. The products will carry
Farmako’s branding, an important step in building brand awareness
and loyalty with physicians, pharmacists and patients. The products
initially include high potency THC flower and balanced THC and CBD
flower, two product categories that management believes are in
highest demand in Germany. Shipments to Farmako are expected to
start in November 2020.
Farmako CEO Katrin Eckmans stated: “It is our
intention to establish partnerships with reliable suppliers and
ensure high quality and sustainable supply at a fair price range to
German patients. ZenPharm and Zenabis have proven themselves as
trustful and reliable supply partners. Our goal to provide
sustainable product for German patients takes a big step forward
with this transaction, and my team is excitedly working on our
product launch to occur later this year.”
About AgraFlora Organics International
Inc.AgraFlora Organics International Inc. is a leading
cannabis company building shareholder value through the development
of revenue generating operating assets in the global cannabis
industry. AgraFlora is focused primarily on the Canadian cannabis
industry; the world’s most advanced and regulated legal cannabis
market. Flagship Canadian assets include: Edibles & Infusions,
a fully automated manufacturing facility in Winnipeg, MB for
white-label and consumer branded edible production; Propagation
Services Canada, a large-scale commercial greenhouse in Delta, BC
focused on reshaping the Canadian flower market with high-potency,
low cost cannabis flower, and AAA Heidelberg, a craft focused
cannabis producer in London, ON. In addition, AgraFlora’s wholly
owned subsidiary Farmako GmbH is scaling towards its goal of being
Europe’s leading distributor of medical cannabis. Farmako currently
has active distribution operations in Germany and expects to
commence active operations in the United Kingdom in 2020. For more
information please visit: https://agraflora.com/.
About Farmako GmbHFarmako GmbH
is a pharmaceutical wholesaler based in Frankfurt, Germany. The
company focuses on the distribution of medical cannabis to
pharmacies with the aim of securing the supply for cannabis
patients and closing the gap between supply and demand for medical
cannabis. Farmako is planning to expand its business model into
other European countries with a corresponding legal basis, scaling
towards its goal of being Europe’s leading distributor of medicinal
cannabis. The company already distributes medical cannabis to
pharmacies in Germany since March 2019 and is fully licenses in the
UK to start distribution operations there in 2020. Farmako is a
100% subsidiary of AgraFlora Organics International Inc. For more
information please visit: https://www.farmako-global.com/.
ON BEHALF OF THE BOARD OF
DIRECTORSNicholas KonkinE: ir@agraflora.comT:
(800) 783-6056
For French inquiries:Maricom
Inc.Remy ScalabriniE: rs@maricom.ca T: (888) 585-MARI
The CSE and Information Service Provider have not
reviewed and does not accept responsibility for the accuracy or
adequacy of this release.
Forward-looking Information Cautionary
StatementExcept for statements of historic fact this news
release contains certain “forward-looking information” within the
meaning of applicable securities law. Forward-looking information
is frequently characterized by words such as “plan” “expect”
“project” “intend” “believe” “anticipate” “estimate” and other
similar words or statements that certain events or conditions “may”
or “will” occur. Forward-looking statements are based on the
opinions and estimates at the date the statements are made and are
subject to a variety of risks and uncertainties and other factors
that could cause actual events or results to differ materially from
those anticipated in the forward-looking statements including but
not limited to delays or uncertainties with regulatory approvals
including that of the CSE. There are uncertainties inherent in
forward-looking information including factors beyond the Company’s
control. There are no assurances that the business plans for
AgraFlora Organics described in this news release will come into
effect on the terms or time frame described herein. The Company
undertakes no obligation to update forward-looking information if
circumstances or management’s estimates or opinions should change
except as required by law. The reader is cautioned not to place
undue reliance on forward-looking statements. Additional
information identifying risks and uncertainties that could affect
financial results is contained in the Company’s filings with
Canadian securities regulators which are available at
www.sedar.com.
Agra Ventures (CSE:AGRA)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Agra Ventures (CSE:AGRA)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024